Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Astrocytoma Treatment Drug Market to Witness Upsurge in Growth During the Study…

Key Takeaways from the Astrocytoma Market Report Key Takeaways from the Astrocytoma Market Report Discover which therapies are expected to grab the major astrocytoma market share @ Astrocytoma Market Report Astrocytoma Overview Astrocytoma is a type of cancer that originates in the astrocytes, star-shaped cells in the brain and spinal cord that support nerve cells. Symptoms of astrocytoma vary depending on its location and size but commonly include headaches, seizures, memory...

Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During…

Key Takeaways from the Complement Inhibitors Market Report Key Takeaways from the Complement Inhibitors Market Report Discover which therapies are expected to grab the complement inhibitors market share @ Complement Inhibitors Market Report Complement Inhibitors Market Dynamics The complement inhibitors market has been witnessing significant growth, driven by the increasing prevalence of autoimmune and inflammatory diseases. Asresearch and development in immunology advance,...

WuXi Biologics Reports Solid 2024 Interim Results

Financial Highlights Financial Highlights Business Highlights Management Comment Dr.Chris Chen, CEO of WuXi Biologics, stated, "Amid a dynamic macroeconomic and geopolitical environment, our business has demonstrated strong resilience. This is attributed to our unique CRDMO business model which we believe is the most efficient for our industry, as well as the successful implementation of our 'Follow and Win the Molecule' strategies. In the first half of 2024, we added 61 new...

Orion Corporation: Managers' transactions – Niclas Lindstedt

ORION CORPORATIONMANAGERS' TRANSACTIONS21 AUGUST 2024 at 18.45 EEST Orion Corporation: Managers' transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...

BCMA-Targeted Therapies Market to Witness Upsurge in Growth During the Study…

Key Takeaways from the BCMA-Targeted Therapies Market Report Key Takeaways from the BCMA-Targeted Therapies Market Report Discover which therapies are expected to grab the BCMA-targeted therapies market share @ BCMA-Targeted Therapies Market Report BCMA-Targeted Therapies Market Dynamics The BCMA-targeted therapies market has witnessed significant growth and interest, primarily driven by their promising potential in treating multiple myeloma. The advent of BCMA-targeted...

Microsampling Devices Market worth $135 million by 2029 driven by Shifting…

Browse in-depth TOC on "Microsampling Devices Market" Browse in-depth TOC on "Microsampling Devices Market" 292 - Tables 42 - Figures 268 - Pages Tasso, Inc.: Market Leader in Microsampling Devices Tasso, Inc. (US) is a leading player in the microsampling devices market, holding the largest market share in 2023. Since its inception, Tasso's products have been widely used in pharmaceutical clinical trials and across many hospitals in the US. The company leverages both...

Toffeln Announces Acquisition of Avail Medical

The collaboration between Toffeln and Avail Medical is founded on a shared commitment to improving the wellbeing and efficiency of healthcare workers. "This union represents a great step forward in our mission to support healthcare professionals with the best possible products and services," said Ben Turner, Managing Director of Toffeln. "By bringing together our complementary strengths, we are poised to enabling better healthcare for staff as well as patients." The…

Ultrasound Market to be Worth $18.07 billion by 2031 - Exclusive Report by…

The report offers a competitive landscape based on an extensive assessment of product offerings, geographical presence, and key growth strategies adopted by prominent market players over the past three to four years. The key players profiled in the ultrasound market study are GE Healthcare Technologies Inc. (U.S.), Konica Minolta, Inc. (Japan), Koninklijke Philips N.V. (Netherlands), Siemens Healthineers AG (Germany), Canon Inc. (Japan), Esaote S.p.A (Italy), Shenzhen Mindray Bio-Medical…

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

Additionally, UTime intends to launch a variety of products focusing on smart detection of key health indicators, such as heart rate and sleep monitoring devices. Additionally, UTime intends to launch a variety of products focusing on smart detection of key health indicators, such as heart rate and sleep monitoring devices. Hengcong Qiu, Chairman of UTime, commented, "We believe that our strategic cooperation with Dr.Ehud Baronand our AI-enabled healthcare initiatives will spearhead key...

Hain Celestial Unlocks Fuel For Growth Through Productivity and Sourcing, Cash…

Introduced in September 2023, Hain Reimagined outlined comprehensive plans to transform the company into a globally integrated enterprise to drive scale and deliver long-term shareholder value. A key aspect of the strategy is unlocking fuel for growth, which is comprised of revenue growth management, cash management and operational efficiencies to fund the transformation. Introduced inSeptember 2023, Hain Reimagined outlined comprehensive plans to transform the company into a globally...

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug.21, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an...

Hemodynamic Monitoring Devices Market to Reach $1.9 Billion, Globally, by 2033…

Request Sample of the Report on Hemodynamic Monitoring Devices Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/A122626 Prime determinants of growth The hemodynamic monitoring market is being propelled by several key drivers such as technological advancements such as the development of minimally invasive devices and wearable sensors are enhancing patient comfort and providing real-time data. The increasing prevalence of cardiovascular diseases and...

SciBase changes Certified Adviser to Carnegie Investment Bank AB (publ)

For additional information, please contact:Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.comCertified Advisor (CA): For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail:pia.renaudin@scibase.com Certified Advisor (CA): Vator Securities Tel: +46 8 580 065 99 Email: ca@vatorsec.se About SciBase: SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase...

Implantica publishes Interim Report January - June 2024 (Q2)

Significant events after the end of the period Significant events after the end of the period Financial summary second quarter 2024 First six months Telephone conference Implantica will hold a teleconference on21 August 2024at 15:00 (CEST) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast If you wish to participate via webcast, please use...

Interim report- SciBase

The second quarter in figures The second quarter in figures January - June in figures Important events during the quarter Important events after the end of the period Financial overview This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onAugust 21, 2024. This interim...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch,...

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Martin Olin, Chief Executive Officer of BerGenBio stated: Martin Olin, Chief Executive Officer of BerGenBio stated: "The BGBC016 clinical trial continued to progress well during the quarter. An independent review of the final cohort in the Ph1b part showed acceptable safety allowing initiation of the 2 nddose in the Ph2a part, and we completed the activation of the Ph2a sites. We now look forward to sharing preliminary efficacy data from the Ph2a portion of the study as they mature...

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides…

Oslo, August 21, 2024:Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its second quarter 2024 results today. Conference call and webcast scheduled for August 21, 2024, at 14:00 (CET). Link to webcast here .Second Quarter 2024 Business UpdateFollowing the negative INITIUM result in March 2024, Ultimovacs implemented cash preservation initiatives during the second quarter of 2024...

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1, Galapagos received a transparency notification on 16 August 2024 from FMR LLC, who notified that it holds 3,696,750 of Galapagos' voting rights, consisting of 3,693,550 ordinary shares and 3,200 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management...

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 20 August 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...

Brains Bioceutical Set to Achieve One of the World's First CEP for Cannabidiol…

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

PI3K Inhibitors Market to Observe Stunning Growth During the Study Period…

Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox…

Astrocytoma Treatment Drug Market to Witness Upsurge in Growth During the Study…

Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During…

WuXi Biologics Reports Solid 2024 Interim Results

Orion Corporation: Managers' transactions – Niclas Lindstedt

BCMA-Targeted Therapies Market to Witness Upsurge in Growth During the Study…

Microsampling Devices Market worth $135 million by 2029 driven by Shifting…

Toffeln Announces Acquisition of Avail Medical

Ultrasound Market to be Worth $18.07 billion by 2031 - Exclusive Report by…

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

Hain Celestial Unlocks Fuel For Growth Through Productivity and Sourcing, Cash…

OKYO Pharma Announces Chairman Acquires Shares

Hemodynamic Monitoring Devices Market to Reach $1.9 Billion, Globally, by 2033…

SciBase changes Certified Adviser to Carnegie Investment Bank AB (publ)

Implantica publishes Interim Report January - June 2024 (Q2)

Interim report- SciBase

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China…

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides…

Galapagos receives transparency notification from FMR LLC

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…